Danish pharmaceutical large Novo Nordisk, which grew to become probably the most invaluable firm in Europe final yr because of the blockbuster success of its weight reduction medication, on Thursday beat revenue estimates for the primary quarter.

Web revenue rose 28% year-on-year to 25.4 billion Danish kroner ($3.65 billion), versus analyst expectations of 23.7 billion kroner, in line with LSEG information.

Gross sales of standard weight reduction drug Wegovy greater than doubled to 9.38 billion kroner.

This can be a breaking information story and shall be up to date shortly.